| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680472 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2018 | 16 Pages |
Abstract
The AD drug development pipeline is slightly larger in 2018 than in 2017. Trials increasingly include preclinical and prodromal populations. There is an increase in nonamyloid mechanisms of action for drugs in earlier phases of drug development. Biomarkers are increasingly used in AD drug development but are not used uniformly for AD diagnosis confirmation.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Jeffrey Cummings, Garam Lee, Aaron Ritter, Kate Zhong,